A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer
A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Inclusion Criteria:
Cohort 1A Inclusion Criteria:
Cohort C Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
CABA, 1199, Argentina
N. Faliro, 18547, Greece
Gyöngyös - Mátraháza, Heves County 3233, Hungary
Romania, 400015, Romania
Majadahonda - Madrid, 28222, Spain